

GOOD SKIN GLOWS

*Confidence
shines*

ONE TREATMENT AND UP TO 6 MONTHS OF FEELING GREAT^{1,2,*,†,‡}

With **Juvéderm® VOLITE** you can improve your patients' skin quality attributes — increasing smoothness[§], hydration and elasticity — for up to 6 months with just one treatment.^{2,†,‡}

Utilising patented VYCROSS® technology,³ **Juvéderm® VOLITE** is injected intradermally and can be used for areas such as the face, neck, décolletage and hands.⁴

When your patients glow on the outside, they feel great inside.^{2,5}



References:

1. Allergan Data on File INT/0655/2016. Juvéderm® VOLITE Clinical Study (V12-001), 6 months top line, patient satisfaction results. Sep, 2016. 2. Allergan Data on File INT/0653/2016. Juvéderm® VOLITE Clinical Study (V12-001), 6 months top line, summary. Sep, 2016. 3. Lebreton P, 2004. Réticulation de polysaccharides de faible et forte masse moléculaire; préparation d'hydrogels monophasiques injectables; polysaccharides et hydrogels obtenus. Publication number: WO 2004/092222 A2. 4. Juvéderm® VOLITE DFU. 73140JR10, Revision 2016-02-19. 5. Allergan Data on File INT/0448/2016(1). Allergan Skin Quality Market Research Insights. Jul, 2016. 6. Allergan Data on File INT/0773/2016. Juvéderm® VOLITE Names. Oct, 2016. 7. Goodman GJ et al. *Plast Reconstr Surg*. 2015;136:139S-48S.

Footnotes:

* Based on FACE-Q satisfaction with skin mean score improvements at Month 1=64.6%, Month 4=60.3%, and Month 6=57.7% (p<0.001). Baseline satisfaction was 43.5%.¹

† After a single treatment, which included initial (n=131) and top-up administered at Day 30 (n=31).²

‡ Study conducted using Juvéderm® VOLITE B without lidocaine.⁵ Added lidocaine enhances patient comfort during injections and has no substantive effect on the rheological properties of HA products.⁷

§ Smoothness is defined as the absence of fine lines.

|| Cheek skin hydration (secondary endpoint) improved significantly from baseline at Months 1, 4 and 6. Skin smoothness (primary endpoint) improved in patients at Month 1 (96.2%), Month 4 (76.3%) and Month 6 (34.9%). Five of the 10 cheek skin elasticity parameters (secondary endpoint) improved significantly from baseline at Month 1 and 4 but not Month 6.²

Please refer to the Juvéderm® VOLITE Directions For Use for further information.⁴

Preparation date: November 2016. Job number: INT/0732/2016.

GOOD SKIN
GLOWS
*Confidence
 shines*

ONE TREATMENT AND UP TO 6 MONTHS OF FEELING GREAT^{1,2,*;†,‡}

With **Juvéderm® VOLITE** you can improve your patients' skin quality attributes — increasing smoothness,[§] hydration and elasticity — for up to 6 months with just one treatment.^{2,†,‡}

Utilising patented VYCROSS® technology,³ **Juvéderm® VOLITE** is injected intradermally and can be used for areas such as the face, neck, décolletage and hands.⁴

When your patients glow on the outside, they feel great inside.^{2,5}



References:

1. Allergan Data on File INT/0655/2016. Juvéderm® VOLITE Clinical Study (V12-001), 6 months top line, patient satisfaction results. Sep, 2016. 2. Allergan Data on File INT/0653/2016. Juvéderm® VOLITE Clinical Study (V12-001), 6 months top line, summary. Sep, 2016. 3. Lebreton P, 2004. Réticulation de polysaccharides de faible et forte masse moléculaire; préparation d'hydrogels monophasiques injectables; polysaccharides et hydrogels obtenus. Publication number: WO 2004/092222 A2. 4. Juvéderm® VOLITE DFU. 73140JR10, Revision 2016-02-19. 5. Allergan Data on File INT/0448/2016(1). Allergan Skin Quality Market Research Insights. Jul, 2016. 6. Allergan Data on File INT/0773/2016. Juvéderm® VOLITE Names. Oct, 2016. 7. Goodman GJ et al. *Plast Reconstr Surg*. 2015;136:139S–48S.

Footnotes:

* Based on FACE-Q satisfaction with skin mean score improvements at Month 1=64.6%, Month 4=60.3%, and Month 6=57.7% (p<0.001). Baseline satisfaction was 43.5%.¹

† After a single treatment, which included initial (n=131) and top-up administered at Day 30 (n=31).²

‡ Study conducted using Juvéderm® VOLITE B without lidocaine.⁶ Added lidocaine enhances patient comfort during injections and has no substantive effect on the rheological properties of HA products.⁷

§ Smoothness is defined as the absence of fine lines.

|| Cheek skin hydration (secondary endpoint) improved significantly from baseline at Months 1, 4 and 6. Skin smoothness (primary endpoint) improved in patients at Month 1 (96.2%), Month 4 (76.3%) and Month 6 (34.9%). Five of the 10 cheek skin elasticity parameters (secondary endpoint) improved significantly from baseline at Month 1 and 4 but not Month 6.²

Please refer to the Juvéderm® VOLITE Directions For Use for further information.⁴

Preparation date: November 2016. Job number: INT/0732/2016.

GOOD SKIN GLOWS

Confidence
shines

ONE TREATMENT AND UP TO 6 MONTHS OF FEELING GREAT^{1,2,*,†,‡}

With **Juvéderm® VOLITE** you can improve your patients' skin quality attributes — increasing smoothness,[§] hydration and elasticity — for up to 6 months with just one treatment.^{2,†,‡}

Utilising patented VYCROSS® technology,³ **Juvéderm® VOLITE** is injected intradermally and can be used for areas such as the face, neck, décolletage and hands.⁴

When your patients glow on the outside, they feel great inside.^{2,5}



References:

1. Allergan Data on File INT/0655/2016. Juvéderm® VOLITE Clinical Study (V12-001), 6 months top line, patient satisfaction results. Sep, 2016. 2. Allergan Data on File INT/0653/2016. Juvéderm® VOLITE Clinical Study (V12-001), 6 months top line, summary. Sep, 2016. 3. Lebreton P, 2004. Réticulation de polysaccharides de faible et forte masse moléculaire; préparation d'hydrogels monophasiques injectables; polysaccharides et hydrogels obtenus. Publication number: WO 2004/092222 A2. 4. Juvéderm® VOLITE DFU, 73140JR10, Revision 2016-02-19. 5. Allergan Data on File INT/0448/2016(1). Allergan Skin Quality Market Research Insights. Jul, 2016. 6. Allergan Data on File INT/0773/2016. Juvéderm® VOLITE Names. Oct, 2016. 7. Goodman GJ et al. *Plast Reconstr Surg.* 2015;136:139S–48S.

Footnotes:

* Based on FACE-Q satisfaction with skin mean score improvements at Month 1=64.6%, Month 4=60.3%, and Month 6=57.7% (p<0.001). Baseline satisfaction was 43.5%.¹

† After a single treatment, which included initial (n=131) and top-up administered at Day 30 (n=31).²

‡ Study conducted using Juvéderm® VOLITE B without lidocaine.⁵ Added lidocaine enhances patient comfort during injections and has no substantive effect on the rheological properties of HA products.⁷

§ Smoothness is defined as the absence of fine lines.

|| Cheek skin hydration (secondary endpoint) improved significantly from baseline at Months 1, 4 and 6. Skin smoothness (primary endpoint) improved in patients at Month 1 (96.2%), Month 4 (76.3%) and Month 6 (34.9%). Five of the 10 cheek skin elasticity parameters (secondary endpoint) improved significantly from baseline at Month 1 and 4 but not Month 6.²

Please refer to the Juvéderm® VOLITE Directions For Use for further information.⁴

Preparation date: November 2016. Job number: INT/0732/2016.

GOOD SKIN GLOWS

*Confidence
shines*

ONE TREATMENT AND UP TO 6 MONTHS OF FEELING GREAT^{1,2,*;†,‡}

With **Juvéderm® VOLITE** you can improve your patients' skin quality attributes — increasing smoothness,[§] hydration and elasticity — for up to 6 months with just one treatment.^{2,†,‡}

Utilising patented VYCROSS® technology,³ **Juvéderm® VOLITE** is injected intradermally and can be used for areas such as the face, neck, décolletage and hands.⁴

When your patients glow on the outside, they feel great inside.^{2,5}



VOLITE

References:

1. Allergan Data on File INT/0655/2016. Juvéderm® VOLITE Clinical Study (V12-001), 6 months top line, patient satisfaction results. Sep, 2016. 2. Allergan Data on File INT/0653/2016. Juvéderm® VOLITE Clinical Study (V12-001), 6 months top line, summary. Sep, 2016. 3. Lebreton P, 2004. Réticulation de polysaccharides de faible et forte masse moléculaire; préparation d'hydrogels monophasiques injectables; polysaccharides et hydrogels obtenus. Publication number: WO 2004/092222 A2. 4. Juvéderm® VOLITE DFU, 73140JR10, Revision 2016-02-19. 5. Allergan Data on File INT/0448/2016(1). Allergan Skin Quality Market Research Insights. Jul, 2016. 6. Allergan Data on File INT/0773/2016. Juvéderm® VOLITE Names. Oct, 2016. 7. Goodman GJ et al. *Plast Reconstr Surg*. 2015;136:139S–48S.

Footnotes:

* Based on FACE-Q satisfaction with skin mean score improvements at Month 1=64.6%, Month 4=60.3%, and Month 6=57.7% (p<0.001). Baseline satisfaction was 43.5%.¹

† After a single treatment, which included initial (n=131) and top-up administered at Day 30 (n=31).²

‡ Study conducted using Juvéderm® VOLITE B without lidocaine.⁴ Added lidocaine enhances patient comfort during injections and has no substantive effect on the rheological properties of HA products.⁷

§ Smoothness is defined as the absence of fine lines.

|| Cheek skin hydration (secondary endpoint) improved significantly from baseline at Months 1, 4 and 6. Skin smoothness (primary endpoint) improved in patients at Month 1 (96.2%), Month 4 (76.3%) and Month 6 (34.9%). Five of the 10 cheek skin elasticity parameters (secondary endpoint) improved significantly from baseline at Month 1 and 4 but not Month 6.²

Please refer to the Juvéderm® VOLITE Directions For Use for further information.⁴

Preparation date: November 2016. Job number: INT/0732/2016.

GOOD SKIN GLOWS

Confidence shines

ONE TREATMENT AND UP TO 6 MONTHS OF FEELING GREAT^{1,2,*;†,‡}

With **Juvederm® VOLITE** you can improve your patients' skin quality attributes — increasing smoothness,[§] hydration and elasticity — for up to 6 months with just one treatment.^{2,†,||}

Utilising patented VYCROSS® technology,³ **Juvederm® VOLITE** is injected intradermally and can be used for areas such as the face, neck, décolletage and hands.⁴

When your patients glow on the outside, they feel great inside.^{2,5}



References:
 1. Allergan Data on File INT/0655/2016. Juvederm® VOLITE Clinical Study (V12-001), 6 months top line, patient satisfaction results. Sep, 2016. 2. Allergan Data on File INT/0653/2016. Juvederm® VOLITE Clinical Study (V12-001), 6 months top line, summary. Sep, 2016. 3. Lebreton P, 2004. Réticulation de polysaccharides de faible et forte masse moléculaire; préparation d'hydrogels monophasiques injectables; polysaccharides et hydrogels obtenus. Publication number: WO 2004/092222 A2. 4. Juvederm® VOLITE DFU, 7314QJR10, Revision 2016-02-19. 5. Allergan Data on File INT/0448/2016(1). Allergan Skin Quality Market Research Insights. Jul, 2016. 6. Allergan Data on File INT/0773/2016. Juvederm® VOLITE Names. Oct, 2016. 7. Goodman GJ et al. *Plast Reconstr Surg*. 2015;136:139S-48S.

Footnotes:
 * Based on FACE-Q satisfaction with skin mean score improvements at Month 1=64.6%, Month 4=60.3%, and Month 6=57.7% (p<0.001). Baseline satisfaction was 43.5%.¹
 † After a single treatment, which included initial (n=131) and top-up administered at Day 30 (n=31).²
 ‡ Study conducted using Juvederm® VOLITE B without lidocaine.⁵ Added lidocaine enhances patient comfort during injections and has no substantive effect on the rheological properties of HA products.⁷
 § Smoothness is defined as the absence of fine lines.
 || Cheek skin hydration (secondary endpoint) improved significantly from baseline at Months 1, 4 and 6. Skin smoothness (primary endpoint) improved in patients at Month 1 (96.2%), Month 4 (76.3%) and Month 6 (34.9%). Five of the 10 cheek skin elasticity parameters (secondary endpoint) improved significantly from baseline at Month 1 and 4 but not Month 6.²
 Please refer to the Juvederm® VOLITE Directions For Use for further information.⁴

GOOD SKIN GLOWS

Confidence shines

ONE TREATMENT AND UP TO 6 MONTHS OF FEELING GREAT^{1,2,*,†,‡}

With Juvéderm® VOLITE you can improve your patients' skin quality attributes — increasing smoothness,[§] hydration and elasticity — for up to 6 months with just one treatment.^{2,†,‡}

Utilising patented VYCROSS® technology,³ Juvéderm® VOLITE is injected intradermally and can be used for areas such as the face, neck, décolletage and hands.⁴

When your patients glow on the outside, they feel great inside.^{2,5}



VOLITE

References:

1. Allergan Data on File INT/0655/2016. Juvéderm® VOLITE Clinical Study (V12-001), 6 months top line, patient satisfaction results. Sep, 2016. 2. Allergan Data on File INT/0653/2016. Juvéderm® VOLITE Clinical Study (V12-001), 6 months top line, summary. Sep, 2016. 3. Lebreton P, 2004. Réticulation de polysaccharides de faible et forte masse moléculaire; préparation d'hydrogels monophasiques injectables; polysaccharides et hydrogels obtenus. Publication number: WO 2004/092222 A2. 4. Juvéderm® VOLITE DFU, 7314QJR10, Revision 2016-02-19. 5. Allergan Data on File INT/0448/2016(1). Allergan Skin Quality Market Research Insights. Jul, 2016. 6. Allergan Data on File INT/0773/2016. Juvéderm® VOLITE Names. Oct, 2016. 7. Goodman GJ et al. *Plast Reconstr Surg*. 2015;136:139S-48S.

Footnotes:

* Based on FACE-Q satisfaction with skin mean score improvements at Month 1=64.6%, Month 4=60.3%, and Month 6=57.7% (p<0.001). Baseline satisfaction was 43.5%.¹

† After a single treatment, which included initial (n=131) and top-up administered at Day 30 (n=31).²

‡ Study conducted using Juvéderm® VOLITE B without lidocaine.⁵ Added lidocaine enhances patient comfort during injections and has no substantive effect on the rheological properties of HA products.⁷

§ Smoothness is defined as the absence of fine lines.

|| Cheek skin hydration (secondary endpoint) improved significantly from baseline at Months 1, 4 and 6. Skin smoothness (primary endpoint) improved in patients at Month 1 (96.2%), Month 4 (76.3%) and Month 6 (34.9%). Five of the 10 cheek skin elasticity parameters (secondary endpoint) improved significantly from baseline at Month 1 and 4 but not Month 6.²

Please refer to the Juvéderm® VOLITE Directions For Use for further information.⁴

Preparation date: November 2016. Job number: INT/0732/2016.